MedDataX Logo

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

NCT ID: NCT00159770

Last Updated: 2021-02-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-11-30

Study Completion Date

2004-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients

NCT00159757

Schizophrenia
TERMINATED PHASE4

Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia

NCT00139737

Schizophrenia
COMPLETED PHASE3

A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

NCT00645515

Schizophrenia
TERMINATED PHASE3

Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder

NCT00137020

Schizophrenia Psychotic Disorders
COMPLETED PHASE4

Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

NCT00174447

Schizophrenia
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizoaffective Disorder Psychotic Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ziprasidone versus olanzapine , risperidone or quetiapine

Intervention Type DRUG

Panss , CGI-C, UKU-SERS-Pa

Intervention Type BEHAVIORAL

Blood tests

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV).
* Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator

Exclusion Criteria

* A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Aalborg, , Denmark

Site Status

Pfizer Investigational Site

Arhus C, , Denmark

Site Status

Pfizer Investigational Site

Augustenborg, , Denmark

Site Status

Pfizer Investigational Site

Ballerup Municipality, , Denmark

Site Status

Pfizer Investigational Site

Brovst, , Denmark

Site Status

Pfizer Investigational Site

Copenhagen, , Denmark

Site Status

Pfizer Investigational Site

Dianalund, , Denmark

Site Status

Pfizer Investigational Site

Esbjerg, , Denmark

Site Status

Pfizer Investigational Site

Esbjerg N, , Denmark

Site Status

Pfizer Investigational Site

Glostrup Municipality, , Denmark

Site Status

Pfizer Investigational Site

Haderslev, , Denmark

Site Status

Pfizer Investigational Site

Holbæk, , Denmark

Site Status

Pfizer Investigational Site

Kjellerup, , Denmark

Site Status

Pfizer Investigational Site

Kolding, , Denmark

Site Status

Pfizer Investigational Site

København S, , Denmark

Site Status

Pfizer Investigational Site

Lemvig, , Denmark

Site Status

Pfizer Investigational Site

Odense C, , Denmark

Site Status

Pfizer Investigational Site

Ringkøbing, , Denmark

Site Status

Pfizer Investigational Site

Risskov, , Denmark

Site Status

Pfizer Investigational Site

Vejle, , Denmark

Site Status

Pfizer Investigational Site

Viborg, , Denmark

Site Status

Pfizer Investigational Site

Vordingborg, , Denmark

Site Status

Pfizer Investigational Site

Forssa, , Finland

Site Status

Pfizer Investigational Site

Helsinki, , Finland

Site Status

Pfizer Investigational Site

Järvenpää, , Finland

Site Status

Pfizer Investigational Site

Kiviranta, , Finland

Site Status

Pfizer Investigational Site

Mikkeli, , Finland

Site Status

Pfizer Investigational Site

Turku, , Finland

Site Status

Pfizer Investigational Site

Tuusula, , Finland

Site Status

Pfizer Investigational Site

Reykjavik, , Iceland

Site Status

Pfizer Investigational Site

Basel, Canton of Basel-City, Switzerland

Site Status

Pfizer Investigational Site

Bern, Canton of Bern, Switzerland

Site Status

Pfizer Investigational Site

Sankt Gallen, Canton of St. Gallen, Switzerland

Site Status

Pfizer Investigational Site

Lausanne, Canton of Vaud, Switzerland

Site Status

Pfizer Investigational Site

Prangins, Canton of Vaud, Switzerland

Site Status

Pfizer Investigational Site

Zurich, Canton of Zurich, Switzerland

Site Status

Pfizer Investigational Site

Bulle, , Switzerland

Site Status

Pfizer Investigational Site

Chêne-Bourg, , Switzerland

Site Status

Pfizer Investigational Site

Delémont, , Switzerland

Site Status

Pfizer Investigational Site

Oetwil, , Switzerland

Site Status

Pfizer Investigational Site

Riehen, , Switzerland

Site Status

Pfizer Investigational Site

Saint Urban, , Switzerland

Site Status

Pfizer Investigational Site

Solothurn, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark Finland Iceland Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A1281079

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study
NCT00645320 COMPLETED PHASE4
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCT00645229 TERMINATED PHASE3
Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia
NCT00265382 TERMINATED PHASE3
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
NCT00649064 COMPLETED PHASE4
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
NCT00458211 COMPLETED PHASE4
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
NCT00555997 COMPLETED PHASE2
Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
NCT00257192 TERMINATED PHASE3
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
NCT00649844 COMPLETED PHASE3
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
NCT01006551 COMPLETED PHASE2
Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia
NCT01260116 UNKNOWN
Effectiveness of Ziprasidone for Patients With Schizophrenia
NCT01198353 COMPLETED PHASE4
Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade
NCT00225498 COMPLETED NA
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
NCT00634348 COMPLETED PHASE4
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCT00650429 COMPLETED PHASE4
Treatment of Schizophrenic Patients With Ziprasidone
NCT00579670 COMPLETED
A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients
NCT00645372 COMPLETED PHASE3
Efficacy and Safety With Ziprasidone in First-episode Psychosis
NCT01157559 COMPLETED PHASE4
IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)
NCT00136994 COMPLETED PHASE3
The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation
NCT02935998 UNKNOWN PHASE4
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
NCT01795547 COMPLETED PHASE3
Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
NCT00224315 COMPLETED PHASE4
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms
NCT00403546 COMPLETED PHASE3
Ziprasidone in the Psychosis Prodrome
NCT00635700 COMPLETED PHASE2
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
NCT00723606 COMPLETED PHASE3
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
NCT01714011 COMPLETED PHASE4